Inceptionr LLC Makes New $936,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Inceptionr LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, Holdings Channel reports. The firm acquired 7,003 shares of the life sciences company’s stock, valued at approximately $936,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ILMN. WCM Investment Management LLC increased its holdings in Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the last quarter. ARK Investment Management LLC purchased a new stake in Illumina during the 4th quarter worth approximately $91,714,000. Massachusetts Financial Services Co. MA increased its holdings in Illumina by 148.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after purchasing an additional 631,294 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after purchasing an additional 625,245 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in Illumina by 116.9% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock worth $115,663,000 after purchasing an additional 466,519 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Down 1.2 %

Shares of ILMN stock opened at $84.65 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The stock has a fifty day moving average of $119.36 and a two-hundred day moving average of $131.84. The firm has a market capitalization of $13.41 billion, a PE ratio of -11.02, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ILMN. Robert W. Baird lowered their price target on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday. Royal Bank of Canada lowered their price target on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and lowered their price target for the company from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Citigroup lowered their price target on Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a report on Tuesday. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus price target of $149.25.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.